Selected research
Market Structure
Global GABAB Receptor Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global GABAB Receptor Agonists market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for GABAB Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for GABAB Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for GABAB Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for GABAB Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of GABAB Receptor Agonists include Xi'an Libang Pharmaceuticals, Xi'an Hanfeng Pharmaceuticals, Sun Pharma, Hemony Pharmaceutical, Sichuan Ren'an Pharmaceuticals, Novartis, Nanjing Haina Pharmaceutical, China Resources Double Crane Pharmaceuticals and Fuan Pharmaceutical Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global GABAB Receptor Agonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of GABAB Receptor Agonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents GABAB Receptor Agonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GABAB Receptor Agonists market size, projected growth trends, production technologies, key applications, and end-use industries.
GABAB Receptor Agonists Segment by Company
Xi'an Libang Pharmaceuticals
Xi'an Hanfeng Pharmaceuticals
Sun Pharma
Hemony Pharmaceutical
Sichuan Ren'an Pharmaceuticals
Novartis
Nanjing Haina Pharmaceutical
China Resources Double Crane Pharmaceuticals
Fuan Pharmaceutical Group
Chengdu Beite
Viatris
Jazz Pharmaceuicals
Hikma
GABAB Receptor Agonists Segment by Type
Baclofen
γ-hydroxybutyrate(GHB))
GABAB Receptor Agonists Segment by Application
Hospital
Clinic
Other
GABAB Receptor Agonists Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GABAB Receptor Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GABAB Receptor Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GABAB Receptor Agonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the GABAB Receptor Agonists market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of GABAB Receptor Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of GABAB Receptor Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of GABAB Receptor Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Baclofen
- γ-hydroxybutyrate(GHB))
Applications
- Hospital
- Clinic
- Other
Companies covered
- Xi'an Libang Pharmaceuticals
- Xi'an Hanfeng Pharmaceuticals
- Sun Pharma
- Hemony Pharmaceutical
- Sichuan Ren'an Pharmaceuticals
- Novartis
- Nanjing Haina Pharmaceutical
- China Resources Double Crane Pharmaceuticals
- Fuan Pharmaceutical Group
- Chengdu Beite
- Viatris
- Jazz Pharmaceuicals
- Hikma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global GABAB Receptor Agonists Market Size, 2021 VS 2025 VS 2032
- 1.3 Global GABAB Receptor Agonists Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global GABAB Receptor Agonists Sales Estimates and Forecasts (2021-2032)
- 1.5 Global GABAB Receptor Agonists Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global GABAB Receptor Agonists Market Dynamics
- 2.1 GABAB Receptor Agonists Industry Trends
- 2.2 GABAB Receptor Agonists Industry Drivers
- 2.3 GABAB Receptor Agonists Industry Opportunities and Challenges
- 2.4 GABAB Receptor Agonists Industry Restraints
3 GABAB Receptor Agonists Market by Manufacturers
- 3.1 Global GABAB Receptor Agonists Revenue by Manufacturers (2021-2026)
- 3.2 Global GABAB Receptor Agonists Sales by Manufacturers (2021-2026)
- 3.3 Global GABAB Receptor Agonists Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global GABAB Receptor Agonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global GABAB Receptor Agonists Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global GABAB Receptor Agonists Manufacturers, Product Type & Application
- 3.7 Global GABAB Receptor Agonists Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global GABAB Receptor Agonists Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 GABAB Receptor Agonists Players Market Share by Revenue in 2025
- 3.8.3 2025 GABAB Receptor Agonists Tier 1, Tier 2, and Tier 3
4 GABAB Receptor Agonists Market by Type
- 4.1 GABAB Receptor Agonists Type Introduction
- 4.1.1 Baclofen
- 4.1.2 γ-hydroxybutyrate(GHB))
- 4.2 Global GABAB Receptor Agonists Sales by Type
- 4.2.1 Global GABAB Receptor Agonists Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global GABAB Receptor Agonists Sales by Type (2021-2032)
- 4.2.3 Global GABAB Receptor Agonists Sales Market Share by Type (2021-2032)
- 4.3 Global GABAB Receptor Agonists Revenue by Type
- 4.3.1 Global GABAB Receptor Agonists Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global GABAB Receptor Agonists Revenue by Type (2021-2032)
- 4.3.3 Global GABAB Receptor Agonists Revenue Market Share by Type (2021-2032)
5 GABAB Receptor Agonists Market by Application
- 5.1 GABAB Receptor Agonists Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Other
- 5.2 Global GABAB Receptor Agonists Sales by Application
- 5.2.1 Global GABAB Receptor Agonists Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global GABAB Receptor Agonists Sales by Application (2021-2032)
- 5.2.3 Global GABAB Receptor Agonists Sales Market Share by Application (2021-2032)
- 5.3 Global GABAB Receptor Agonists Revenue by Application
- 5.3.1 Global GABAB Receptor Agonists Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global GABAB Receptor Agonists Revenue by Application (2021-2032)
- 5.3.3 Global GABAB Receptor Agonists Revenue Market Share by Application (2021-2032)
6 Global GABAB Receptor Agonists Sales by Region
- 6.1 Global GABAB Receptor Agonists Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global GABAB Receptor Agonists Sales by Region (2021-2032)
- 6.2.1 Global GABAB Receptor Agonists Sales by Region (2021-2026)
- 6.2.2 Global GABAB Receptor Agonists Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America GABAB Receptor Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America GABAB Receptor Agonists Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe GABAB Receptor Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe GABAB Receptor Agonists Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific GABAB Receptor Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific GABAB Receptor Agonists Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa GABAB Receptor Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa GABAB Receptor Agonists Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global GABAB Receptor Agonists Revenue by Region
- 7.1 Global GABAB Receptor Agonists Revenue by Region
- 7.1.1 Global GABAB Receptor Agonists Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global GABAB Receptor Agonists Revenue by Region (2021-2026)
- 7.1.3 Global GABAB Receptor Agonists Revenue by Region (2027-2032)
- 7.1.4 Global GABAB Receptor Agonists Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America GABAB Receptor Agonists Revenue (2021-2032)
- 7.2.2 North America GABAB Receptor Agonists Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe GABAB Receptor Agonists Revenue (2021-2032)
- 7.3.2 Europe GABAB Receptor Agonists Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific GABAB Receptor Agonists Revenue (2021-2032)
- 7.4.2 Asia-Pacific GABAB Receptor Agonists Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa GABAB Receptor Agonists Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa GABAB Receptor Agonists Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Xi'an Libang Pharmaceuticals
- 8.1.1 Xi'an Libang Pharmaceuticals Company Information
- 8.1.2 Xi'an Libang Pharmaceuticals Business Overview
- 8.1.3 Xi'an Libang Pharmaceuticals GABAB Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Xi'an Libang Pharmaceuticals GABAB Receptor Agonists Product Portfolio
- 8.1.5 Xi'an Libang Pharmaceuticals Recent Developments
- 8.2 Xi'an Hanfeng Pharmaceuticals
- 8.2.1 Xi'an Hanfeng Pharmaceuticals Company Information
- 8.2.2 Xi'an Hanfeng Pharmaceuticals Business Overview
- 8.2.3 Xi'an Hanfeng Pharmaceuticals GABAB Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Xi'an Hanfeng Pharmaceuticals GABAB Receptor Agonists Product Portfolio
- 8.2.5 Xi'an Hanfeng Pharmaceuticals Recent Developments
- 8.3 Sun Pharma
- 8.3.1 Sun Pharma Company Information
- 8.3.2 Sun Pharma Business Overview
- 8.3.3 Sun Pharma GABAB Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Sun Pharma GABAB Receptor Agonists Product Portfolio
- 8.3.5 Sun Pharma Recent Developments
- 8.4 Hemony Pharmaceutical
- 8.4.1 Hemony Pharmaceutical Company Information
- 8.4.2 Hemony Pharmaceutical Business Overview
- 8.4.3 Hemony Pharmaceutical GABAB Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Hemony Pharmaceutical GABAB Receptor Agonists Product Portfolio
- 8.4.5 Hemony Pharmaceutical Recent Developments
- 8.5 Sichuan Ren'an Pharmaceuticals
- 8.5.1 Sichuan Ren'an Pharmaceuticals Company Information
- 8.5.2 Sichuan Ren'an Pharmaceuticals Business Overview
- 8.5.3 Sichuan Ren'an Pharmaceuticals GABAB Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Sichuan Ren'an Pharmaceuticals GABAB Receptor Agonists Product Portfolio
- 8.5.5 Sichuan Ren'an Pharmaceuticals Recent Developments
- 8.6 Novartis
- 8.6.1 Novartis Company Information
- 8.6.2 Novartis Business Overview
- 8.6.3 Novartis GABAB Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Novartis GABAB Receptor Agonists Product Portfolio
- 8.6.5 Novartis Recent Developments
- 8.7 Nanjing Haina Pharmaceutical
- 8.7.1 Nanjing Haina Pharmaceutical Company Information
- 8.7.2 Nanjing Haina Pharmaceutical Business Overview
- 8.7.3 Nanjing Haina Pharmaceutical GABAB Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Nanjing Haina Pharmaceutical GABAB Receptor Agonists Product Portfolio
- 8.7.5 Nanjing Haina Pharmaceutical Recent Developments
- 8.8 China Resources Double Crane Pharmaceuticals
- 8.8.1 China Resources Double Crane Pharmaceuticals Company Information
- 8.8.2 China Resources Double Crane Pharmaceuticals Business Overview
- 8.8.3 China Resources Double Crane Pharmaceuticals GABAB Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 China Resources Double Crane Pharmaceuticals GABAB Receptor Agonists Product Portfolio
- 8.8.5 China Resources Double Crane Pharmaceuticals Recent Developments
- 8.9 Fuan Pharmaceutical Group
- 8.9.1 Fuan Pharmaceutical Group Company Information
- 8.9.2 Fuan Pharmaceutical Group Business Overview
- 8.9.3 Fuan Pharmaceutical Group GABAB Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Fuan Pharmaceutical Group GABAB Receptor Agonists Product Portfolio
- 8.9.5 Fuan Pharmaceutical Group Recent Developments
- 8.10 Chengdu Beite
- 8.10.1 Chengdu Beite Company Information
- 8.10.2 Chengdu Beite Business Overview
- 8.10.3 Chengdu Beite GABAB Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Chengdu Beite GABAB Receptor Agonists Product Portfolio
- 8.10.5 Chengdu Beite Recent Developments
- 8.11 Viatris
- 8.11.1 Viatris Company Information
- 8.11.2 Viatris Business Overview
- 8.11.3 Viatris GABAB Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Viatris GABAB Receptor Agonists Product Portfolio
- 8.11.5 Viatris Recent Developments
- 8.12 Jazz Pharmaceuicals
- 8.12.1 Jazz Pharmaceuicals Company Information
- 8.12.2 Jazz Pharmaceuicals Business Overview
- 8.12.3 Jazz Pharmaceuicals GABAB Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Jazz Pharmaceuicals GABAB Receptor Agonists Product Portfolio
- 8.12.5 Jazz Pharmaceuicals Recent Developments
- 8.13 Hikma
- 8.13.1 Hikma Company Information
- 8.13.2 Hikma Business Overview
- 8.13.3 Hikma GABAB Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Hikma GABAB Receptor Agonists Product Portfolio
- 8.13.5 Hikma Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 GABAB Receptor Agonists Value Chain Analysis
- 9.1.1 GABAB Receptor Agonists Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 GABAB Receptor Agonists Production Mode & Process
- 9.2 GABAB Receptor Agonists Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 GABAB Receptor Agonists Distributors
- 9.2.3 GABAB Receptor Agonists Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst